Navigation Links
Biolaxy Secures IND Approval for Oral Insulin
Date:11/24/2009

SHANGHAI, Nov. 24 /PRNewswire-Asia/ -- Shanghai Biolaxy announced the Chinese State Food & Drug Administration (SFDA) has approved the investigational new drug application (IND) for its oral insulin project (Nodlin), an innovative insulin formulation to treat diabetes. This IND approval allows Biolaxy to initiate its first phase I clinical study.

Diabetes is a disorder characteristic of high blood glucose and poor metabolism. The complications of diabetes often result in severe micro- and macro-vascular diseases, loss of vision, kidney failure, and amputation. Insulin, as an effective diabetic treatment, can slow down diabetic disease progression. However, insulin is given by multiple daily injections at present, which significantly hinders its use.

Oral drug administration is a preferred route. However, the gastrointestinal (GI) tract is designed to digest nutrients like proteins and presents significant challenges for oral insulin including enzyme degradation and poor absorption. Currently, there is no approved oral insulin product despite intensive research in this field.

Nodlin is developed with NOD technology, a patented bio-adhesive nano-particle oral delivery technology, to overcome the barriers of oral insulin.

"IND approval is a significant milestone achievement for Biolaxy," quoted from William Lee, CEO. "We have experienced long delay in the approval process due to regulatory uncertainties, but we are very happy now Biolaxy is back on track in full speed to develop urgently needed drugs for the patients."

    For more information, please contact:

     William Lee, Ph.D., CEO
     Phone: +86-21-6194-0758
     Email: info@biolaxy.com

    Press Contact
     Qianyu Zhao, Ph.D., Director of R&D
     Phone: +86-21-6194-0858 x807
     Email: info@biolaxy.com


    Notes for Editors

About Diabetes and Insulin Treatment

Diabetes has reached epidemic stage. It is estimated that there are 30-40 million diabetic patients in China with 1.2 million new cases each year. Insulin is a key diabetic treatment with worldwide market value close to $10 billion. Diabetic patients have to endure multiple daily injections for life and patients often are reluctant to use insulin despite the clinical proven benefits of early insulin treatment. Currently, insulin treatment in China particularly is under used.

About Biolaxy

Shanghai Biolaxy is a development stage biotech company and emerging leader in innovative delivery for biopharmaceuticals. Biolaxy was established in 2005 and is a wholly owned subsidiary of NOD Pharmaceuticals. Biolaxy uses patented platform technology, nano-particle oral delivery or NOD technology, to develop oral formulations for biopharmaceuticals, including insulin, exenatide, interferon, human growth hormone and more.

Nodlin is the first candidate developed with NOD technology and is positioned as basal insulin formulation based on the pre-clinical data. Nodlin possesses unique pharmacokinetic profile and is highly competitive.

More information can be found at http://www.biolaxy.com .

SOURCE Shanghai Biolaxy


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Osteotech Secures 10-Year Tissue Supply Agreement
2. Shire Secures European Wide Label Extension for FOSRENOL(R) in Chronic Kidney Disease
3. Corgenix Secures $1,750,000 Asset Based Credit Facility Representing Initial Gross Proceeds of $1.109 Million
4. LS9 Secures $25 Million in Latest Round of Funding
5. Neurocrine Biosciences Secures Committed Equity Financing Facility
6. OpenQ Secures Investment from Leading Mid-Atlantic Venture Firm
7. Cappella Inc. Secures $17.3 Million Series C Investment
8. SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Germany & Austria
9. Sinobiopharma Secures Rights to Seven Key Patents
10. Aerovance Secures $38 Million in Equity Financing
11. VIA Pharmaceuticals Secures Financing Up to $10.0 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... San Diego-based ... of its corporate rebranding initiative announced today. The bold new look is part ... as the company moves into a significant growth period. , It will also expand ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board meeting in North Carolina, ... Harvard University’s Departments of Physics and Astronomy, has been selected for membership in ... team for the 2015 Breakthrough Prize in Fundamental physics for the discovery of the ...
(Date:10/7/2017)...  The 2017 Nobel Prize in Chemistry recognizes ... Joachim Frank and Richard Henderson ... (cryo-EM) have helped to broaden the use ... The winners worked with systems manufactured by Thermo ... resolved, three-dimensional images of protein structures that lead ...
Breaking Biology Technology:
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:3/30/2017)... 2017  On April 6-7, 2017, Sequencing.com will host ... hackathon at Microsoft,s headquarters in Redmond, ... on developing health and wellness apps that provide a ... Genome is the first hackathon for personal genomics ... companies in the genomics, tech and health industries are ...
Breaking Biology News(10 mins):